The effects of amlodipine 5 to 10 mg/day on hypertension and metabolic indices was assessed in 113 patients with recently diagnosed untreated mild hypertension, and non-insulin-dependent diabetes mellitus [NIDDM). Comparisons were made with normotensive patients matched with similar demographic and clinical characteristics. Amlodipine showed notable antihypertensive efficacy without affecting heart rate. It had no negative effect on glucose homeostasis (HbA(lc) and blood glucose levels), β-cell secretion or serum lipid profile, although lipoprotein A levels increased. No progression of ocular or cardiac disease was noted during treatment with the drug, indicating a possible protective effect. Eight of 82 (9.7%) treated hypertensive patients and 6 of 78 (7.7%) normotensive patients with normal urinary albumin excretion rates (AER) at baseline developed microalbuminuria after 52 weeks. No patient with microalbuminuria developed proteinuria. Opposing significant intergroup differences in AER were noted for normotensive (increased; p <0.05) and hypertensive (decreased; not significant) patients with baseline microalbuminuria. Together, these results suggest a renoprotective role for amlodipine in this setting. In conclusion, amlodipine is an effective antihypertensive agent that has no negative long term effect on glucose homeostasis, β-cell secretion or lipid profile in patients with mild hypertension and NIDDM.
|Number of pages||11|
|Journal||Clinical Drug Investigation|
|Issue number||SUPPL. 1|
|Publication status||Published - 1997|
ASJC Scopus subject areas
- Pharmacology (medical)